Rachel Springate, general partner at Muse Capital, said the next wave of healthcare startups will be driven by consumer demand — but pure direct-to-consumer models rarely work. Companies like Midi Health, Mavida Health and Mahmee are showing a different path: starting with patients, collecting outcomes data, and integrating with clinicians, payers and the broader healthcare system.
Bristol Myers Squibb plaque psoriasis drug Sotyktu will be the first product available at a steep discount to eligible cash-pay patients who use BMS Patient Connect, a new online platform set to launch in January. Direct-to-patient sales could offer one way for pharma companies to address President Trump’s call for lower drug prices.
MedCity News was at the Vive conference and spoke with executives who shared their insights for the healthcare industry.
But where do truth and trust originate in healthcare marketing? They emerge from various sources such as digital advertising, educational campaigns, patient journeys, and partnerships with healthcare providers who uphold truth in advertising standards.
To address the complicated healthcare landscape in the U.S., Pfizer launched a new direct-to-consumer virtual service called PfizerForAll. It follows Eli Lilly, which launched a similar product in January.
Function Health, a membership-based platform that gives consumers access to more than 100 different lab tests, closed a Series A financing round that brought its total funding to date to $53 million. The round was led by Andreessen Horowitz and included a slew of celebrity investors, including Matt Damon, Zac Efron, Blake Griffin and Colin Kaepernick.
In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.
Arbiter’s Anjali Jameson on hospital and payer alignment.
Funding for digital health is blowing up, and the sky’s the limit for a healthcare world suddenly, and solidly, committed to tech innovations. Here’s what we can expect to see more of next year.
The company plans to pair its direct-to-consumer genetic testing with Lemonaid’s online coaching and prescription delivery. It plans to buy the company for $400 million in stock and cash.
The startup, where patients access cash-pay telehealth and in-person visits, recently added prescription delivery through Truepill. It’s offering a list of generic medications for $5.
Opportunities exist in many areas of the industry, and patients are hungrier than ever for more engaging and humane experiences. For D2C brands that are ready to capitalize on the changing market, the sky's the limit.
How to turn analytics into actual policy outcomes.
While D2C can enable creativity in customer acquisition and B2B strategies allow for rapid monetization, companies must thoughtfully target consumers, track clinical outcomes, and demonstrate cost-savings.
Covid-19 showed that pharma companies can be nimble and implement changes that prevent processes from weighing down on operations. But which of these operational and strategic changes will stand the test of time and make this year and the future bright for the industry?
The three-year-old digital health startup began trading on the New York Stock Exchange on Thursday. It merged with a subsidiary of Oaktree Capital Management in a deal that valued the company at $1.6 billion.
A.G. Breitenstein, a founding partner with Optum Ventures, launched FOLX on Thursday. The direct-to-consumer health platform is designed specifically with LGBTQ patients in mind.
The Bay Area hearing device-maker planned to raise $141.3 million in an upsized IPO. Its stock started trading on Nasdaq under the ticker “EAR.”